Biogen Hirulog licensed to The Medicines Company for $30 mil..
Executive Summary
BIOGEN LICENSES HIRULOG TO THE MEDICINES COMPANY FOR $30 MIL. in upfront fees, milestone payments and development commitments, plus royalties on Hirulog sales, The Medicines Company announced March 25. Cambridge, Mass.-based TMC notes that its "deal structures are arranged to include royalties and milestone payments to the originating pharmaceutical company if market performance of a product exceeds the expectation of both parties." In return, TMC holds exclusive worldwide rights to develop and sell the synthetic leech protein derivative Hirulog (bivalirudin).
You may also be interested in...
It Has Been A Long Farewell To The Medicines Company
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force
The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.
TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force
The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.